Acute Ischaemic Stroke in a COVID-19 Patient on Baricitinib - A Causal Effect or a Multifactorial Relationship?

Coronavirus disease 2019 (COVID-19), a multisystemic disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been associated with both venous and arterial thromboses. The hypercoagulable state of the poses challenge to patient’s management. We herein report case ischaemic stroke in COVID-19 patient who had treated three days Baricitinib, an immunotherapy that can potentially augment thrombotic risks. highlights dilemma faced when initiating emphasises importance evaluating risks, balanced against benefit immunotherapy, facilitate selection ideal candidates for immunotherapy.